Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.
The Evolution of ALK+ NSCLC Care
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.